H.C. Wainwright assumed coverage of Syndax (SNDX) with a Buy rating and $40 price target The firm has conviction that Revuforj will expand its footprint across the relapsed/refractory setting. Revuforj is emerging as the foundational menin inhibitor in acute myeloid leukemia, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Strategic Positioning and Competitive Edge: Syndax Pharmaceuticals’ Buy Rating Reinforced by Revuforj’s Milestones in Leukemia Treatment
- Syndax announces updated NCCN Guidelines for AML
- Synopsys downgraded, Oracle upgraded: Wall Street’s top analyst calls
- 3 Best Stocks to Buy Now, 9/10/2025, According to Top Analysts
- Syndax resumed with a Buy at Stifel